Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04354857
Other study ID # IRB: 20.04.09
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 27, 2020
Est. completion date November 30, 2020

Study information

Verified date June 2021
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.


Recruitment information / eligibility

Status Completed
Enrollment 454
Est. completion date November 30, 2020
Est. primary completion date July 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients presenting with COVID-19 related symptoms including: fever, persistent cough, fatigue, shortness of breath, diarrhoea, abdominal pain, chest pain, sore throat, loss of smell or taste - Subjects in prolonged contact with COVID-19 infected patients. Exclusion Criteria: - Patients directly admitted to the intensive care unit were excluded - Patients opposing use of their health data

Study Design


Related Conditions & MeSH terms


Intervention

Other:
olfactory and gustatory tests
Participants rate quality of sense of smell and taste. Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor. Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste

Locations

Country Name City State
France CHU de Nimes Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary SARS-CoV-2 infection status Positive/negative according to RT-PCR assay Day 0
Primary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Day 0
Secondary Ability to detect odor Ability to smell 1.5ml air freshner on a 0-100 VAS scale Day 0
Secondary Ability to detect odor Ability to smell 1.5ml air freshner on a 0-100 VAS scale Six months
Secondary Ability to detect salty taste Ability to taste a pinch of table salt on a 0-100 VAS scale Day 0
Secondary Ability to detect salty taste Ability to taste a pinch of table salt on a 0-100 VAS scale Six months
Secondary Ability to detect sweet taste Ability to taste a pinch of sugar on a 0-100 VAS scale Day 0
Secondary Ability to detect sweet taste Ability to taste a pinch of sugar on a 0-100 VAS scale Six months
Secondary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Day 7
Secondary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Day 14
Secondary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Day 30
Secondary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Day 60
Secondary Severity of infection according to hospitalization rate % patients hospitalized End of study (six months)
Secondary Olfactory and gustatory loss Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) Six months
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure